WO2005077332A3 - Formes posologiques stables de gabapentine pour usage oral et a liberation prolongee, et procede de preparation associe - Google Patents

Formes posologiques stables de gabapentine pour usage oral et a liberation prolongee, et procede de preparation associe Download PDF

Info

Publication number
WO2005077332A3
WO2005077332A3 PCT/IB2005/000093 IB2005000093W WO2005077332A3 WO 2005077332 A3 WO2005077332 A3 WO 2005077332A3 IB 2005000093 W IB2005000093 W IB 2005000093W WO 2005077332 A3 WO2005077332 A3 WO 2005077332A3
Authority
WO
WIPO (PCT)
Prior art keywords
gabapentin
preparation
dosage forms
oral dosage
release oral
Prior art date
Application number
PCT/IB2005/000093
Other languages
English (en)
Other versions
WO2005077332A2 (fr
Inventor
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Manish Chawla, Rajeev Singh Raghuvanshi, Ashok Rampal filed Critical Ranbaxy Lab Ltd
Publication of WO2005077332A2 publication Critical patent/WO2005077332A2/fr
Publication of WO2005077332A3 publication Critical patent/WO2005077332A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

L'invention concerne des formes posologiques stables de gabapentine pour usage oral et à libération prolongée, leurs procédés de préparation, et leurs utilisations dans le traitement de l'épilepsie ou de la névralgie post-herpétique.
PCT/IB2005/000093 2004-01-19 2005-01-17 Formes posologiques stables de gabapentine pour usage oral et a liberation prolongee, et procede de preparation associe WO2005077332A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN83DE2004 2004-01-19
IN83/DEL/2004 2004-01-19

Publications (2)

Publication Number Publication Date
WO2005077332A2 WO2005077332A2 (fr) 2005-08-25
WO2005077332A3 true WO2005077332A3 (fr) 2006-07-27

Family

ID=34856866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000093 WO2005077332A2 (fr) 2004-01-19 2005-01-17 Formes posologiques stables de gabapentine pour usage oral et a liberation prolongee, et procede de preparation associe

Country Status (2)

Country Link
CN (1) CN1921839A (fr)
WO (1) WO2005077332A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077492A1 (fr) * 2005-01-24 2006-07-27 Ranbaxy Laboratories Limited Formes dosifiées orales à libération prolongée de gabapentine
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
CN104352460A (zh) * 2014-10-21 2015-02-18 齐宏 一种加巴喷丁片剂及其制备方法
CN106333927A (zh) * 2015-07-08 2017-01-18 昆山龙灯瑞迪制药有限公司 修饰释放的尼麦角林组合物
CN110917164B (zh) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 一种苯磺酸米洛巴林缓释片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059572A1 (fr) * 1998-05-15 1999-11-25 Warner-Lambert Company Compositions solides contenant des derives de l'acide gamma-aminobutyrique, et procede de preparation associe
WO2003035040A1 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Methodes de traitement a l'aide d'un dosage de gabapentine a retenue gastrique
WO2003103634A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formes posologiques orales a liberation prolongee de gabapentine
WO2005020978A1 (fr) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Comprimes de gabapentine a liberation prolongee et a administration par voie orale et leurs procedes de preparation
WO2005046566A2 (fr) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Composition pharmaceutique stable

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059572A1 (fr) * 1998-05-15 1999-11-25 Warner-Lambert Company Compositions solides contenant des derives de l'acide gamma-aminobutyrique, et procede de preparation associe
WO2003035040A1 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Methodes de traitement a l'aide d'un dosage de gabapentine a retenue gastrique
WO2003103634A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formes posologiques orales a liberation prolongee de gabapentine
WO2005046566A2 (fr) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Composition pharmaceutique stable
WO2005020978A1 (fr) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Comprimes de gabapentine a liberation prolongee et a administration par voie orale et leurs procedes de preparation

Also Published As

Publication number Publication date
WO2005077332A2 (fr) 2005-08-25
CN1921839A (zh) 2007-02-28

Similar Documents

Publication Publication Date Title
WO2005077332A3 (fr) Formes posologiques stables de gabapentine pour usage oral et a liberation prolongee, et procede de preparation associe
JO2858B1 (en) Pharmaceutical dosage images
WO2003063794A3 (fr) Composes 2,4-pyrimidinediamine et leurs utilisations
WO2005070390A3 (fr) Solution orale de mitratapide
EP2982696A3 (fr) Traitement de la leucémie lymphoblastique aiguë
WO2007127505A3 (fr) Composés chimiques
MA31245B1 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
WO2007103105A3 (fr) Procédés de préparation de produits à base de morphinan-6-one avec de faibles niveaux de composés de cétones alpha, bêta-insaturées
WO2007064618A8 (fr) Méthodes pour traiter une perte musculaire
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2007068894A3 (fr) Nouveaux composes
WO2003088923A3 (fr) Procedes relatifs au traitement de l'occlusion intestinale
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2006034491A3 (fr) Composes a base de quinoleine et de quinazoline a substitution phenylique pour le traitement du diabete
WO2007016352A3 (fr) Compositions orales liquides de losartan
WO2004017948A8 (fr) Utilisation d'inhibiteur lck pour le traitement d'affections immunologiques
WO2006110588A3 (fr) Methodes permettant de traiter les troubles cognitifs moderes
ATE399165T1 (de) Chinolinverbindungen und deren verwendungen
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
WO2007006732A8 (fr) Combinaison synergique pour traiter une douleur (agoniste du recepteur canabinoide et agoniste du recepteur opioide)
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
WO2006089286A3 (fr) Composes utiles pour traiter et prevenir la douleur et procedes de criblage associes
WO2005112923A3 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
WO2007007182A3 (fr) Formes galeniques solides d'agent antiepileptique
WO2007144699A3 (fr) Procédé pour la préparation d'alfuzosine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 4233/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580005953.6

Country of ref document: CN

122 Ep: pct application non-entry in european phase